Provigil data

Data from the first of two double-blind, placebo-controlled Phase III trials of CEPH's oral drug for narcolepsy showed Provigil to have a statistically significant benefit in reducing excessive daytime sleepiness.

Results were measured by the maintenance of wakefulness test (MWT) and a physician-perceived measure of benefit to the patient (CGI-C), the study's two primary end points. ...